Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul;22(4):307-11.
doi: 10.1097/CCO.0b013e32833aa9de.

Erythropoietin in cancer patients: pros and cons

Mario Dicato  1 , Laurent Plawny
Affiliations
Review

Erythropoietin in cancer patients: pros and cons

Mario Dicato et al. Curr Opin Oncol. 2010 Jul.

Abstract

Purpose of review: Anaemia is a frequent complication of cancer. Recently, some concerns have appeared regarding the safety of erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia in cancer patients. The current review will analyse the main arguments in favour of erythropoietin (EPO), as well as those against EPO in chemotherapy-induced anaemia and in cancer-related anaemia. The principal concerns are tumour progression, increased mortality and the risk of venous thromboembolic events (VTEs). Recent meta-analyses have come to divergent conclusions.

Recent findings: Several meta-analyses have reviewed the data regarding VTEs, EPO receptors on tumours and tumour progression as well as mortality.

Summary: As of now, ESAs should only be used within the indications as given in the various guidelines.

PubMed Disclaimer